Nurix Therapeutics (NRIX) Cash & Current Investments (2019 - 2025)
Historic Cash & Current Investments for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $592.9 million.
- Nurix Therapeutics' Cash & Current Investments fell 273.01% to $592.9 million in Q4 2025 from the same period last year, while for Nov 2025 it was $592.9 million, marking a year-over-year decrease of 273.01%. This contributed to the annual value of $592.9 million for FY2025, which is 273.01% down from last year.
- According to the latest figures from Q4 2025, Nurix Therapeutics' Cash & Current Investments is $592.9 million, which was down 273.01% from $428.8 million recorded in Q3 2025.
- In the past 5 years, Nurix Therapeutics' Cash & Current Investments ranged from a high of $609.6 million in Q4 2024 and a low of $244.0 million during Q1 2024
- Over the past 5 years, Nurix Therapeutics' median Cash & Current Investments value was $326.5 million (recorded in 2021), while the average stood at $372.4 million.
- Its Cash & Current Investments has fluctuated over the past 5 years, first tumbled by 2485.67% in 2023, then skyrocketed by 12528.52% in 2025.
- Quarter analysis of 5 years shows Nurix Therapeutics' Cash & Current Investments stood at $295.7 million in 2021, then increased by 4.54% to $309.1 million in 2022, then dropped by 6.87% to $287.9 million in 2023, then soared by 111.73% to $609.6 million in 2024, then decreased by 2.73% to $592.9 million in 2025.
- Its Cash & Current Investments was $592.9 million in Q4 2025, compared to $428.8 million in Q3 2025 and $485.8 million in Q2 2025.